Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-04-19
2011-04-19
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S135100, C424S136100, C424S141100, C424S143100, C424S144100, C424S153100, C424S173100, C530S387100, C530S387300, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730, C530S388750
Reexamination Certificate
active
07927596
ABSTRACT:
The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of DC40L. in one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of DC40L, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/DC40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.
REFERENCES:
patent: 5474771 (1995-12-01), Lederman et al.
patent: 5747037 (1998-05-01), Noelle et al.
patent: 5759808 (1998-06-01), Casterman et al.
patent: 5800988 (1998-09-01), Casterman et al.
patent: 5831012 (1998-11-01), Nilsson et al.
patent: 5840526 (1998-11-01), Casterman et al.
patent: 5843440 (1998-12-01), Pouletty et al.
patent: 5869049 (1999-02-01), Noelle et al.
patent: 5874541 (1999-02-01), Casterman et al.
patent: 5876718 (1999-03-01), Noelle et al.
patent: 5876950 (1999-03-01), Siadak et al.
patent: 5922545 (1999-07-01), Mattheakis et al.
patent: 5977307 (1999-11-01), Friden et al.
patent: 6005079 (1999-12-01), Casterman et al.
patent: 6015695 (2000-01-01), Casterman et al.
patent: 6297053 (2001-10-01), Stemmer
patent: 6328964 (2001-12-01), Noelle et al.
patent: 6340459 (2002-01-01), Yellin et al.
patent: 6375950 (2002-04-01), Noelle et al.
patent: 6696245 (2004-02-01), Winter et al.
patent: 7563443 (2009-07-01), Grant et al.
patent: 2005/0043519 (2005-02-01), Dooley et al.
patent: 2005/0089932 (2005-04-01), Kolkman et al.
patent: 0368684 (1990-05-01), None
patent: 0721469 (1996-07-01), None
patent: 0742721 (1996-11-01), None
patent: 0831906 (1998-04-01), None
patent: 1005372 (2000-06-01), None
patent: WO90/05144 (1990-05-01), None
patent: WO-9005144 (1990-05-01), None
patent: WO90/14430 (1990-11-01), None
patent: WO-9014430 (1990-11-01), None
patent: WO 91/01743 (1991-02-01), None
patent: WO92/01047 (1992-01-01), None
patent: WO-9201047 (1992-01-01), None
patent: WO92/20791 (1992-11-01), None
patent: WO-9220791 (1992-11-01), None
patent: WO-9305236 (1993-03-01), None
patent: WO93/11236 (1993-06-01), None
patent: WO 95/06481 (1995-03-01), None
patent: WO-95/06666 (1995-03-01), None
patent: WO-9506480 (1995-03-01), None
patent: WO-9506481 (1995-03-01), None
patent: WO-9606213 (1996-02-01), None
patent: WO-9640246 (1996-06-01), None
patent: WO-9708320 (1997-03-01), None
patent: WO-98/58965 (1998-12-01), None
patent: WO 99/00143 (1999-01-01), None
patent: WO-9900143 (1999-01-01), None
patent: WO-9920749 (1999-04-01), None
patent: WO-9923221 (1999-05-01), None
patent: WO-0029004 (2000-05-01), None
patent: WO-0069907 (2000-11-01), None
patent: WO01/68860 (2001-09-01), None
patent: WO-0168860 (2001-09-01), None
patent: WO-0190192 (2001-11-01), None
patent: WO 01/94586 (2001-12-01), None
patent: WO-0194586 (2001-12-01), None
patent: WO 02/06485 (2002-01-01), None
patent: WO-0206485 (2002-01-01), None
patent: WO 02/18445 (2002-03-01), None
patent: WO-0218445 (2002-03-01), None
patent: WO-0248193 (2002-06-01), None
patent: WO-03002609 (2003-01-01), None
patent: WO-03031611 (2003-04-01), None
patent: WO-03035694 (2003-05-01), None
patent: WO 2004/003019 (2004-01-01), None
patent: WO-2004003019 (2004-01-01), None
patent: WO-04041865 (2004-05-01), None
patent: WO-2004041862 (2004-05-01), None
patent: WO-2004044011 (2004-05-01), None
patent: WO 2004/058821 (2004-07-01), None
patent: WO 2004/058822 (2004-07-01), None
patent: WO-2004058821 (2004-07-01), None
patent: WO-2004058822 (2004-07-01), None
patent: WO 2005/035572 (2005-04-01), None
patent: WO-2005035572 (2005-05-01), None
patent: WO-2005040229 (2005-05-01), None
Conrath, K. et al.; β-Lactamase Inhibitors Derived from Single-Domain Antibody Fragments Elicited in the Camelidae Antimicrobial Agents and Chemotherapy, Oct. 2001, p. 2807-2812 vol. 45, No. 10.
Hoogenboom, H. R.; “Mix and Match: Building Manifold Binding Sites”; Nature Biotechnology; vol. 15, p. 125-126, Feb. 1997.
Conrath, K. et al., “Camel Single-domain Antibodies as Modular Building Units in Bispecific and Bivalent Antibody Constructs”, The Journal of Biological Chemistry, vol. 276, No. 10, Issue of Mar. 9, 2001, p. 7346-7350.
Smith, B. et al., “Prolonged in Vivo Residence Times of antibody Fragments Associated with Albumin”; Bioconjugate Chem, vol. 12 p. 750-756; 2001.
Reiter, Y. et al. “An Antibody Single-domain Phage Display Library of a Native Heavy Chain Variable Region: Isolation of Functional Single-domain VH Molecules with a Unique Interface”, J. Mol. Biol, 1999, vol. 290, p. 685-698.
Nygren, P. et al., “In Vivo Stabilization of a Human Recombinant CD4 Derivative by Fusion to a Serum-albumin-binding Receptor”, Vaccines, vol. 91, 1991, p. 363-368.
Ghahroudi, et al., “Selection and Identification of Single Domain Antibody Fragments from Camel Heavey-chain Antibodies”; Federation of European Biochemical Societies, 1997, p. 521-526.
Van Der Linden, R. et al., “Induction of Immune Responses and Molecular Cloning of the Heavy Chain Antibody Repertoire of Lama Glama”,Journal of Immunological Methods 2000, p. 185-195.
Stahl, et al. “The Use of Gene Fusions to Protein a And Protein G in Immunology and Biotechnology”, Biomedische Bibl, 1997, p. 66-76.
Waldmann, et al., “The Renal Handling of Low Molecular Weight Proteins”; The Journal of Clinical Investigation, vol. 51, 1972, p. 2162-2174.
Gale Encyclopedia of Medicine, Gale Research, 1999, p. 419.
Hulme & Hardwicke, , “Kidney Function and Structure”, Proc Royal Soc. Medicinevol. 59, 1966, p. 509-512.
Birkett, D. “Pharmacokinetics Made Easy”, 1998, p. 16-24.
Cortez-Retamozo, V., Efficient Tumor Targeting by Single-Domain Antibody Fragments of Camels; Int. J. Cancer, 2002, p. 456-462.
Patentee's Sep. 25, 2006 letter regarding EP05076402.6.
Patentee's Dec. 23, 2005 letter regarding EP03776677.1.
Ward, et al., “Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted fromEscherichia coli”; Letters to Nature; Nature; vol. 341, 1989; p. 544-546.
Van Den Beucken, et al., “Building Novel Binding Ligands to B7.1 and B7.2 Based on Human Antibody Sinigle Variable Light Chain Domains”, J. Mol. Biol.; 2001, vol. 310, p. 591-601.
Holliger et al., “Retargeting Serum Immunoglobulin with Bispecific Diabodies”, 1997,Nature Biotechnology, vol. 15, p. 632-638.
Mulyldermans, S., “Single Domain Camel Antibodies: Current Status”, Molecular Biotechnology, 2001, vol. 74, p. 277-302.
Abuchowski et al.,Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol J. Biol. Chem. 1977, 252:3578-81; American Society for Biochemistry and Molecular Biology; .U.S.
Alderson et al., 1994,Synergistic effects of IL-4 and either GM-CSF or IL-3 on the induction of CD23 expression by human monocytes: regulatory effects of IFN-alpha and IFN-gamma; Cytokine, 6(4):407-13; Academic Press; US.
Aggarwal et al., 2003, Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17; J Biol Chem., 278(3):1910-4; Publisher: American Society for Biochemistry and Molecular Biology; .U.S.
Andoh et al., 2002, Interleukin (IL)-4 and IL-17 synergistically stimulate IL-6 secretion in human colonic myofibroblasts; Int J Mol Med., 10(5):631-4; Publisher: D.A. Spandidos.
Armitage et al., 1992, Molecular and biological characterization of a murine ligand for CD40; Nature 357: 80-82; Publisher: Nature Publishing Group, Engla
Grant Steven
Liu Haiqun
Moulder Kevin
DeCloux Amy
Domantis Limited
Edwards Angell Palmer & & Dodge LLP
Gambel Phillip
Williams Kathleen
LandOfFree
Methods of antagonizing binding of CD40 to CD40L with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of antagonizing binding of CD40 to CD40L with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of antagonizing binding of CD40 to CD40L with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2643794